New Preclinical Models for Angioimmunoblastic T-Cell Lymphoma: Filling the GAP

The authors provide a summary of the pathology, the transcriptional profile and genetic and immune-phenotypic features of human angioimmunoblastic lymphoma (AITL). In addition, they give an overview of preclinical models that recapitulate more or less faithfully human AITL characteristics and pathology.
[Oncogenesis]
Mhaidly, R., Krug, A., Gaulard, P., Lemonnier, F., Ricci, J.-E., & Verhoeyen, E. (2020). New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP. Oncogenesis, 9(8), 1–16. https://doi.org/10.1038/s41389-020-00259-x Cite
Full Article

Continue reading “New Preclinical Models for Angioimmunoblastic T-Cell Lymphoma: Filling the GAP”

Bookmark

No account yet? Register

0
Share

TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma

TG Therapeutics, Inc. announced that the FDA has accepted the company’s New Drug Application for umbralisib, the company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma who have received at least one prior anti-CD20 based regimen and follicular lymphoma who have received at least two prior systemic therapies.
[TG Therapeutics, Inc.]
Press Release

Continue reading “TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma”

Bookmark

No account yet? Register

0
Share

BryoLogyx Announces Cooperative Research and Development Agreement for Bryostatin-1 with National Cancer Institute

BryoLogyx, Inc. announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia and lymphoma.
[BryoLogyx, Inc.]
Press Release

Continue reading “BryoLogyx Announces Cooperative Research and Development Agreement for Bryostatin-1 with National Cancer Institute”

Bookmark

No account yet? Register

0
Share

Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Scientists treated 14 relapsed or refractory diffuse large B-cell lymphoma patients by combining autologous hematopoietic stem cell transplantation and anti-CD19 chimeric antigen receptor T-cell therapy.
[Immunotherapy]
Abstract

Continue reading “Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell for Relapsed or Refractory Diffuse Large B-Cell Lymphoma”

Bookmark

No account yet? Register

0
Share

Infection during the First Year in Patients Treated with CD19 CAR T Cells for Diffuse Large B Cell Lymphoma

The authors analyzed 60 patients with diffuse large B cell lymphoma treated with FDA-approved CD19 chimeric antigen receptor (CAR) T cells and report the incidence, risk factors, and management of infections during the first year after treatment.
[Blood Cancer Journal]
Wudhikarn, K., Palomba, M. L., Pennisi, M., Garcia-Recio, M., Flynn, J. R., Devlin, S. M., Afuye, A., Silverberg, M. L., Maloy, M. A., Shah, G. L., Scordo, M., Dahi, P. B., Sauter, C. S., Batlevi, C. L., Santomasso, B. D., Mead, E., Seo, S. K., & Perales, M.-A. (2020). Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer Journal, 10(8), 1–11. https://doi.org/10.1038/s41408-020-00346-7 Cite
Full Article

Continue reading “Infection during the First Year in Patients Treated with CD19 CAR T Cells for Diffuse Large B Cell Lymphoma”

Bookmark

No account yet? Register

0
Share

LW-213 Induces Cell Apoptosis in Human Cutaneous T-cell Lymphomas by Activating PERK–eIF2α–ATF4–CHOP Axis

Researchers showed that LW-213 dose-dependently inhibited human cutaneous T-cell lymphoma cell lines with IC50 values of around 10 μM, meanwhile it potently inhibited primary leukemia cells derived from peripheral blood of T-cell lymphoma patients.
[Acta Pharmacologica Sinica]
Yu, X., Zhu, M., Wang, J., Li, H., Hu, P., Qing, Y., Wang, X., Wang, H., Wang, Z., Xu, J., Guo, Q., & Hui, H. (2020). LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK–eIF2α–ATF4–CHOP axis. Acta Pharmacologica Sinica, 1–11. https://doi.org/10.1038/s41401-020-0466-7 Cite
Abstract

Continue reading “LW-213 Induces Cell Apoptosis in Human Cutaneous T-cell Lymphomas by Activating PERK–eIF2α–ATF4–CHOP Axis”

Bookmark

No account yet? Register

0
Share

FDA Approves Monjuvi® (Tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

MorphoSys AG and Incyte announced that the FDA has approved Monjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
[MorphoSys AG]
Press Release

Continue reading “FDA Approves Monjuvi® (Tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)”

Bookmark

No account yet? Register

0
Share

Metabolic Conditioning of CD8+ Effector T Cells for Adoptive Cell Therapy

Investigators showed that transient glucose restriction in activated CD8+ effector T cells metabolically primed effector functions and enhanced tumor clearance in mice.
[Nature Metabolism]
Klein Geltink, R. I., Edwards-Hicks, J., Apostolova, P., O’Sullivan, D., Sanin, D. E., Patterson, A. E., Puleston, D. J., Ligthart, N. A. M., Buescher, J. M., Grzes, K. M., Kabat, A. M., Stanczak, M., Curtis, J. D., Hässler, F., Uhl, F. M., Fabri, M., Zeiser, R., Pearce, E. J., & Pearce, E. L. (2020). Metabolic conditioning of CD8 + effector T cells for adoptive cell therapy. Nature Metabolism, 1–14. https://doi.org/10.1038/s42255-020-0256-z Cite
Abstract

Continue reading “Metabolic Conditioning of CD8+ Effector T Cells for Adoptive Cell Therapy”

Bookmark

No account yet? Register

0
Share

Donor Stem Cell-Derived Paroxysmal Nocturnal Hemoglobinuria after Umbilical Cord Blood Transplantation

The authors report here a patient with adult T‐cell leukemia/lymphoma, who developed paroxysmal nocturnal hemoglobinuria seven years after umbilical cord blood transplantation.
[European Journal of Haematology]
Abstract

Continue reading “Donor Stem Cell-Derived Paroxysmal Nocturnal Hemoglobinuria after Umbilical Cord Blood Transplantation”

Bookmark

No account yet? Register

0
Share

US FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma

Kite announced that the FDA has granted accelerated approval to Tecartus™, the first and only approved chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
[Gilead Sciences, Inc.]
Press Release

Continue reading “US FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma”

Bookmark

No account yet? Register

0
Share

IL-21 Stimulates the Expression and Activation of Cell Cycle Regulators and Promotes Cell Proliferation in EBV-Positive Diffuse Large B Cell Lymphoma

Analysis of a rare clinical sample of EBV-positive DLBCL, in combination with a NOD/SCID mouse xenograft model, confirmed the effect of IL-21 on the proliferation of EBV-positive diffuse large B cell lymphoma cells.
[Scientific Reports]
Full Article

Continue reading “IL-21 Stimulates the Expression and Activation of Cell Cycle Regulators and Promotes Cell Proliferation in EBV-Positive Diffuse Large B Cell Lymphoma”

Bookmark

No account yet? Register

0
Share

Characteristics of Cells with Engraftment Capacity within CD34+ Cell Population upon G-CSF and Plerixafor Mobilization

Investigators assessed the hematopoietic stem cell content within the CD34+ fraction of graft samples from three groups of patients: 1-Good Mobilizer patients receiving G-CSF only, 2-Poor Mobilizer (PM) patients receiving G-CSF only, 3-PM patients receiving G-CSF + Plerixafor.
[Leukemia]
Abstract

Continue reading “Characteristics of Cells with Engraftment Capacity within CD34+ Cell Population upon G-CSF and Plerixafor Mobilization”

Bookmark

No account yet? Register

0
Share
Share